ArticlePloS one2025
Uncovering key biomarkers, potential therapeutic targets and development of deep learning model in heart failure.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) represents a significant public health concern, characterized by elevated rates of mortality and morbidity. Recent advancements in gene sequencing technologies have led to the identification of numerous genes associated with heart failure. By utilizing available gene expression data from the Gene Expression Omnibus (GEO) database, we conducted a screening for differentially expressed genes (DEGs) related to heart failure. Key genes were identified through intersection analysis in conjunction with weighted gene co-expression network analysis (WGCNA). Following this, we pinpointed four essential genes (ITIH5, ISLR, ASPN, and FNDC1) by employing functional enrichment analyses, machine learning approaches, protein-protein interaction (PPI) assessments, gene set enrichment analysis (GSEA), and immune infiltration evaluations. Additionally, a novel diagnostic model for heart failure was successfully developed using a deep learning convolutional neural network (CNN), and its diagnostic performance was validated within public datasets. Analysis via single-cell RNA sequencing further indicated stable up-regulation patterns of these genes across various cardiomyocyte types in HF patients. Moreover, the exploration of drug-protein interactions revealed two potential therapeutic drugs targeting the identified key genes, with molecular docking offering a feasible pathway for this connection. In conclusion, we identified four potential key biomarkers closely related to HF and two possibly effective small molecules, which provide significant insights into the molecular mechanisms underlying heart failure and the search for new therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.